Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients.

[1]  A. Gotto,et al.  Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. , 1991, Journal of the American College of Cardiology.

[2]  A. Khaghani,et al.  Relationship of immunosuppression and serum lipids to the development of coronary arterial disease in the transplanted heart. , 1991, International journal of cardiology.

[3]  M. Yacoub,et al.  Haemostatic changes after heart transplantation and their relationship to accelerated coronary sclerosis. , 1991, Transplantation proceedings.

[4]  A. Menkis,et al.  Serial evaluation of lipid profiles and risk factors for development of hyperlipidemia after cardiac transplantation. , 1990, The American journal of cardiology.

[5]  J. Thompson,et al.  Hyperlipidemia after clinical heart transplantation. , 1989, The Journal of heart transplantation.

[6]  J. Stamler,et al.  Frequency of hypercholesterolemia after cardiac transplantation. , 1988, The American journal of cardiology.

[7]  J F Silverman,et al.  Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. , 1988, Journal of the American College of Cardiology.

[8]  G. Beck,et al.  Serum Lp(a) level as a predictor of vein graft stenosis after coronary artery bypass surgery in patients. , 1988, Circulation.

[9]  L. Simons,et al.  Hyperlipidemia after heart transplantation. , 1988, The Journal of heart transplantation.

[10]  W. Bennett,et al.  MODIFICATION OF EXPERIMENTAL NEPHROTOXICITY WITH FISH OIL AS THE VEHICLE FOR CYCLOSPORINE , 1987, Transplantation.

[11]  N. Morton,et al.  Lp(a) lipoprotein as a risk factor for myocardial infarction. , 1986, JAMA.

[12]  H. Deeg,et al.  HIGH CYCLOSPORIN LEVELS AFTER BONE MARROW TRANSPLANTATION ASSOCIATED WITH HYPERTRIGLYCERIDAEMIA , 1986, The Lancet.

[13]  S. Thompson,et al.  HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDY , 1986, The Lancet.

[14]  T. Kjellström,et al.  The fibrinolytic system and coagulation during bezafibrate treatment of hypertriglyceridemia. , 1986, Atherosclerosis.

[15]  J. Walls,et al.  Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. , 1986, British medical journal.

[16]  W. Harris,et al.  Reduction of Plasma Lipids, Lipoproteins, and Apoproteins by Dietary Fish Oils in Patients with Hypertriglyceridemia , 1985 .

[17]  Robert A. Lewis,et al.  Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function , 1985 .

[18]  J. Vollmar,et al.  Effect of bezafibrate during 4.5 years of treatment of hyperlipoproteinaemia. , 1985, Atherosclerosis.

[19]  T. Strom,et al.  Cyclosporine: a new immunosuppressive agent for organ transplantation. , 1984, Annals of internal medicine.

[20]  G. Schlierf,et al.  The effect of bezafibrate on the fibrinolytic enzyme system and the drug interaction with racemic phenprocoumon. , 1978, Atherosclerosis.

[21]  D. Alonso,et al.  Studies on the pathogenesis of atheroarteriosclerosis induced in rabbit cardiac allografts by the synergy of graft rejection and hypercholesterolemia. , 1977, The American journal of pathology.

[22]  M. Frick,et al.  Lp(a) lipoprotein and pre‐β1‐lipoprotein in patients with coronary heart disease , 1974, Clinical genetics.

[23]  J. Kosek,et al.  Heart graft arteriosclerosis. , 1971, Transplantation proceedings.

[24]  C. Cipolla,et al.  Electrophysiologic and haemodynamic correlates in supraventricular tachycardia. , 1989, European heart journal.

[25]  J. Marples,et al.  Comparative study of once and 3-times daily regimens of bezafibrate in patients with primary hyperlipoproteinaemia. , 1981, Current medical research and opinion.

[26]  W. Harris,et al.  The effects of salmon oil upon plasma lipids, lipoproteins, and triglyceride clearance. , 1980, Transactions of the Association of American Physicians.